Attention-Deficit / Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized as a persistent pattern of inattention and/or hyperactivity-impulsivity, affecting individuals throughout their lifetime.1

ADHD is a complex, heterogeneous disorder affecting individuals over the course of their lifetime.1 Symptoms of ADHD begin before age 12 and interfere with functioning or development.

Epidemiology

ADHD affects approximately 11% of school-aged children in the U.S., based on the 2011 National Survey of Children’s Health, in which parents were asked if a healthcare practitioner had ever told them their child had ADD or ADHD.2

The estimated prevalence of adult ADHD in the U.S. is 4.4%.3 This is based on results from semi-structured clinical interviews conducted in 3,199 respondents aged 18-44 in the National Comorbidity Survey Replication (from 2001 to 2003).

Estimates of the prevalence of ADHD vary due to different research methodologies, varying age groups in epidemiological studies, and changes in the diagnostic criteria over time.4

Screening and Diagnosis

The American Academy of Child and Adolescent Psychiatry recommends that screening for ADHD should be a part of every patient’s mental health assessment, and the American Academy of Pediatrics recommends initiating an evaluation for ADHD in school-aged children who present with academic or behavioral problems and symptoms of inattention and/or hyperactivity-impulsivity.4,5

For a diagnosis of ADHD, individuals must meet the DSM-5 criteria.1 According to the DSM-5, an individual must show at least 6 symptoms of inattention and/or at least 6 symptoms of hyperactivity-impulsivity that must have persisted for at least 6 months to a degree that is inconsistent with the developmental level and negatively impacts social, academic, and/or occupational activities. In individuals 17 years or older, at least 5 symptoms of inattention and/or at least 5 symptoms of hyperactivity-impulsivity must be present.

DSM-5 Symptoms of Inattention
Symptoms must occur often
DSM-5 Symptoms of Hyperactivity and Impulsivity
Symptoms must occur often
Fails to give close attention to detail, or makes careless mistakesFidgets, squirms, or taps hands or feet
Has difficulty sustaining attention in tasks or playLeaves seat when sitting is expected
Does not seem to listen when spoken to directlyRuns around or climbs when it is not appropriate
Does not follow through on instructions and fails to finish chores, homework, or work dutiesUnable to play or engage in leisure activities quietly
Shows difficulty in organizing tasksActs “as if driven by a motor” / is "on the go"
Avoids, dislikes, or is reluctant to engage in activities that require sustained mental effortTalks excessively
Loses things needed for tasks or activitiesAnswers questions before the question is fully asked
Is easily distractedHas difficulty waiting for a turn or waiting in lines
Is forgetful in daily activitiesInterrupts or intrudes on others

Additionally, to meet the DSM-5 diagnostic criteria, several of the symptoms must have been present prior to age 12, must be present in two or more settings, must have clear evidence that they interfere with, or reduce the quality of, social, academic or occupational functioning, and must not occur exclusively within the course of schizophrenia or another psychiatric disorder.1

These are not the complete diagnostic criteria.

Diagnosis should be based on a complete history and evaluation of the patient.

Pathophysiology

While its exact cause is unknown, ADHD is thought to be the result of interactions between genetics, neurobiology, and the environment.6,7

The idea that an individual’s unique mix of genetic and environmental pressures influences disease pathology has given rise to a theory that an individual will manifest signs and symptoms of ADHD if and when their cumulative vulnerability exceeds a certain threshold.7 Based on numerous studies of twins, the mean heritability of ADHD has been estimated to be 77%, suggesting it to be among the most heritable of psychiatric disorders.6

Perinatal factors such as preterm birth, smoking and alcohol exposure during pregnancy, and low birth weight have been proposed as risk factors for ADHD.8,9 While the neurobiology of ADHD is not completely understood, it is thought that neurotransmitter dysfunction and dysregulation of various regions in the prefrontal cortex, as well as other areas of the brain, may be associated with symptoms of ADHD.10,11

Navigating ADHD

As there is no cure for ADHD, the primary goal of ADHD management is to help address the core symptoms of inattention and/or hyperactivity-impulsivity.4

Each treatment plan should be individualized, comprehensive, and multimodal, taking into account available pharmacological and non-pharmacological therapies, education, and patient support resources.5 Periodic reassessments should be performed in order to monitor or assess the efficacy and safety of the treatment plan. Evaluation and management of ADHD should continue as long as symptoms are present and cause impairment of daily activities.

Upcoming & Past Conferences in Neuroscience

  • Upcoming

  • Past

American Epilepsy Society (AES), 2024

December 6 - 10, 2024 | Link to Event

Annual Meeting brings together healthcare providers, scientists, advocates, industry, and other professionals dedicated to better outcomes for people with epilepsy.

American Academy of Neurology (AAN), 2025

April 5 - 9, 2025 | Link to Event

Annual meeting in neurology promoting high quality patient-centric care in a variety of topics and specialties through various learning formats.

American Academy of Sleep Medicine (SLEEP), 2025

June 8 - 11, 2025 | Link to Event

Annual meeting of the Associated Professional Sleep Societies, LLC (APSS), which is a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).

U.S. Psychiatric and Mental Health Congress (US Psych), 2024

October 29 - November 2, 2024

National congress on practical psychopharmacology focused on practical, real-world training, covering the latest techniques, treatments, best practices, and evidence-based care.

Trintellix® (vortioxetine)

  • Antidepressant Changes and App Usage Improve MDD Outcomes in Study to Implement the Pathway Platform in Primary Care: A Post Hoc Subgroup Analysis
  • Noninterventional, Retrospective, Prospective, Longitudinal Cohort Study to Assess Antidepressant Treatment Patterns and Outcomes in Individuals With Major Depressive Disorder
  • Vortioxetine vs Standard of Care Antidepressants in Major Depressive Disorder: 24-Week Results From the PatientsLikeMe Observational Study (encore)

European College of Neuropsychopharmacology (ECNP), 2024

September 21 - 24, 2024

Europe's premier meeting in applied and translational neuroscience discussing the latest developments in research, technologies and treatment of brain disorders.

American Society of Clinical Psychopharmacology (ASCP), 2024

May 28 - 31, 2024

Annual meeting bringing perspectives together from academia, NIH, FDA, clinicians and industry on key aspects of neuropsychiatric drug development, pharmacogenetics and personalized interventions.

International College of Neuropsychopharmacology (CINP), 2024

May 23 - 26, 2024

Global annual congress offering a platform for learning about the latest research advances and new treatments in neuropharmacology, psychiatry, and neuroscience.

Professional Society for Health Economics and Outcomes Research (ISPOR), 2024

May 5 - 8, 2024

Leading global conference discussing how to establish, incentivize, and share value sustainable for health systems, patients, and technology developers.

American Psychiatric Association (APA), 2024

May 4 - 8, 2024

Annual meeting attracting the largest audience of psychiatrists and other mental health professionals offering opportunities to learn the latest in effective clinical practice, policy and research advancements.

American Academy of Neurology (AAN), 2024

April 13 - 18, 2024

Annual meeting in neurology promoting high quality patient-centric care in a variety of topics and specialties through various learning formats.

Medication Resources

Adderall XR®

(mixed salts of a single-entity amphetamine product), CII

Intuniv®

(guanfacine)

Mydayis®

(mixed salts of a single-entity amphetamine product), CII

Vyvanse®

(lisdexamfetamine dimesylate), CII